Poisoning the messengers: could tumor endothelial cells acquire drug resistance?
Thomas-Tikhonenko
Andrel
A
Department Of Pathobiology, University Of Pennsylvania, 3800 Spruce Street; Philadelphia, Pennsylvania 19104-6051, USA. andreit@mail.vet.upenn.edu
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology*; D019008:Drug Resistance, Neoplasm; D016228:Endothelial Growth Factors / Q000378:metabolism; D004730:Endothelium, Vascular / Q000187:drug effects*; D015251:Epirubicin / Q000494:pharmacology*; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000378:metabolism; D008222:Lymphokines / Q000378:metabolism; D051379:Mice; D009303:Nasopharyngeal Neoplasms / Q000098:blood supply* / Q000378:metabolism / Q000473:pathology; D009368:Neoplasm Transplantation; D009389:Neovascularization, Pathologic; D014183:Transplantation, Heterologous; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D000903:Antibiotics, Antineoplastic; D016228:Endothelial Growth Factors; D036341:Intercellular Signaling Peptides and Proteins; D008222:Lymphokines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D015251:Epirubicin